Heartflow vs Legend Biotech

Heartflow (HTFL), health care, and Legend Biotech (LEGN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Heartflow is worth $4.1B on the stock market and Legend Biotech $3.1B: Heartflow is valued at 32% more. Heartflow's operating margin in its latest fiscal year was -36.4% and Legend Biotech's -13.3%. Over the past year Heartflow's share price has moved +71.6% and Legend Biotech's -45.6%.

Key facts

Heartflow market value
$4.1B
Legend Biotech market value
$3.1B
Heartflow P/E
70.3
Heartflow revenue
$176MFY to 2025-12-31
Legend Biotech revenue
$1BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Heartflow vs Legend Biotech: every measure side by side
Measure Heartflow Legend Biotech
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$4.1Bhigher$3.1Blower
Revenue$176Mlower$1Bhigher
Earnings-$116.8Mhigher-$296.8Mlower
Employees843lower3,300higher
Total assets$359.5Mlower$1.7Bhigher
Valuation
P/E70.3—
P/S23.5higher3.0lower
P/B14.6higher2.5lower
Dividend yield0.00%0.00%
Profitability
Operating margin-36.4%lower-13.3%higher
Balance sheet
Net assets$300.6Mlower$1Bhigher
Total liabilities$58.8Mlower$731.6Mhigher
Total debt—$319.1M
Cash on hand$44.8Mlower$901.9Mhigher
Price change
Today+0.45%lower+0.75%higher
1 year+71.6%higher-45.6%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Heartflow only (3)

Legend Biotech only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns HTFL · Who owns LEGN

Further comparisons

Learn

Questions and answers

Which is bigger, Heartflow or Legend Biotech?

By market value, Heartflow is the larger: $4.1B against $3.1B for Legend Biotech. By revenue in its latest fiscal year, Legend Biotech is the larger: $1B against $176M for Heartflow.

Which has the higher operating margin?

Legend Biotech: -13.3%, against -36.4% for Heartflow. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Heartflow and Legend Biotech?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Heartflow and 1 holds Legend Biotech.

Cite this page

Funkfolio, “Heartflow vs Legend Biotech”, data as of 18 November 2026. https://funkfolio.com/compare/htfl-vs-legn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.